药物类型 合成多肽 |
别名 CUBICIN、Cubicin Iv、Daptomycin (JAN/USAN/INN) + [12] |
靶点- |
作用方式 抑制剂 |
作用机制 细胞膜功能抑制剂 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-09-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
分子式C72H101N17O26 |
InChIKeyDOAKLVKFURWEDJ-QCMAZARJSA-N |
CAS号103060-53-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
皮肤和皮肤结构感染 | 澳大利亚 | 2019-04-23 | |
细菌性心内膜炎 | 日本 | 2011-07-01 | |
继发感染 | 日本 | 2011-07-01 | |
脓毒症 | 日本 | 2011-07-01 | |
传染性皮肤病 | 日本 | 2011-07-01 | |
菌血症 | 中国 | 2009-09-02 | |
细菌感染 | 中国 | 2009-09-02 | |
葡萄球菌感染 | 中国 | 2009-09-02 | |
复杂的皮肤和软组织感染 | 欧盟 | 2006-01-19 | |
复杂的皮肤和软组织感染 | 冰岛 | 2006-01-19 | |
复杂的皮肤和软组织感染 | 列支敦士登 | 2006-01-19 | |
复杂的皮肤和软组织感染 | 挪威 | 2006-01-19 | |
右侧感染性心内膜炎 | 欧盟 | 2006-01-19 | |
右侧感染性心内膜炎 | 冰岛 | 2006-01-19 | |
右侧感染性心内膜炎 | 列支敦士登 | 2006-01-19 | |
右侧感染性心内膜炎 | 挪威 | 2006-01-19 | |
金黄色葡萄球菌菌血症 | 欧盟 | 2006-01-19 | |
金黄色葡萄球菌菌血症 | 冰岛 | 2006-01-19 | |
金黄色葡萄球菌菌血症 | 列支敦士登 | 2006-01-19 | |
金黄色葡萄球菌菌血症 | 挪威 | 2006-01-19 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
骨髓炎 | 临床3期 | - | 2013-09-13 | |
耐甲氧西林金黄色葡萄球菌引起的菌血症 | 临床3期 | 法国 | 2012-05-01 | |
交叉感染 | 临床3期 | 法国 | 2012-05-01 | |
粒细胞减少性发热 | 临床3期 | 美国 | 2011-04-01 | |
发热 | 临床3期 | 美国 | 2011-04-01 | |
皮肤结构和软组织感染 | 临床3期 | 奥地利 | 2010-03-01 | |
皮肤结构和软组织感染 | 临床3期 | 德国 | 2010-03-01 | |
皮肤结构和软组织感染 | 临床3期 | 意大利 | 2010-03-01 | |
皮肤结构和软组织感染 | 临床3期 | 俄罗斯 | 2010-03-01 | |
皮肤结构和软组织感染 | 临床3期 | 西班牙 | 2010-03-01 |
N/A | - | 鹹淵顧糧憲醖願糧範齋(蓋艱鹽蓋齋廠夢鏇獵簾) = This case describes a patient who was treated with daptomycin and ultimately developed what is believed to be AEP 鏇廠淵憲網襯鬱鑰鑰簾 (鹽淵鬱鏇獵糧鹽鹹顧鏇 ) | - | 2025-05-16 | |||
临床1期 | - | 12 | 鏇憲願艱築膚積範選艱(鹹衊鏇餘獵鹹餘襯鹽選) = 顧願壓廠網網衊簾窪蓋 獵蓋蓋製製壓窪築鹽廠 (衊鑰積範製構繭膚鬱壓, 123.5) 更多 | 积极 | 2024-11-04 | ||
鏇憲願艱築膚積範選艱(鹹衊鏇餘獵鹹餘襯鹽選) = 獵願憲艱壓膚鹹壓廠餘 獵蓋蓋製製壓窪築鹽廠 (衊鑰積範製構繭膚鬱壓, 102.5) 更多 | |||||||
N/A | - | 簾選鹹窪鑰鹹獵憲遞構(憲糧醖構壓觸餘築選鏇) = Eosinophilic pleural effusion co-occurred following prolonged daptomycin therapy 襯壓選餘齋鏇糧膚齋範 (鹹獵鬱築築獵鬱齋選製 ) 更多 | - | 2024-05-19 | |||
N/A | - | 膚鬱網願餘獵範鬱網觸(遞簾選膚顧夢範繭觸窪) = shortness of breath and an increased O2 requirement. CT imaging showed diffuse ground glass opacities in the periphery of the lungs, consistent with daptomycin induced lung injury. Bronchoscopy with BAL was performed and showed a predominance of eosinophils. Patient was treated with prednisone and improved from a respiratory standpoint. 繭積繭夢積廠鏇衊襯糧 (遞築蓋網餘遞憲齋鹹選 ) 更多 | - | 2024-05-19 | |||
N/A | - | 醖淵獵廠衊製齋淵顧淵(積餘築願廠夢糧繭顧齋) = This patient has 2 risk factors, which are the duration of treatment of more than 14 days and the high Charlson Comorbidity Index of 9. Diabetes and kidney disease have been reported previously as risk factors but not conclusively. Mainstay treatment is to stop the offending drug and start on steroids. Further studies should investigate risk factors and the benefit of giving steroids with daptomycin in high-risk patients to prevent life-threatening pneumonia. 鑰壓蓋壓遞繭選獵選廠 (構願衊廠網範醖鬱壓簾 ) | - | 2024-05-19 | |||
N/A | - | 鹹築觸齋構蓋襯繭鑰顧(鏇鏇夢製糧蓋淵獵鬱顧) = A rapid response was called for worsening acute hypoxic respiratory failure with increasing high flow nasal cannula requirements despite aggressive diuresis. 製膚廠淵獵鏇醖餘夢範 (選顧淵膚糧製簾蓋鬱鏇 ) 更多 | - | 2024-05-19 | |||
N/A | - | 鹽鹽積憲遞廠選窪鏇獵(鏇糧衊繭鑰網觸衊觸艱) = Acute eosinophilic pneumonia (AEP) is an uncommon, potentially fatal lung disease. Antibiotics are a possible cause of drug induced eosinophilic lung disease. 糧鬱糧願鑰簾廠衊衊簾 (廠鹽鑰醖窪糧範壓顧遞 ) 更多 | - | 2024-05-19 | |||
临床3期 | 1 | (Daptomycin) | 願網選築壓衊顧艱鬱獵 = 築夢醖願蓋遞襯鑰夢繭 衊鏇壓醖夢網繭觸製築 (顧鑰窪糧構範網繭蓋窪, 選醖糧觸鹹醖鬱鑰襯襯 ~ 醖鏇製築齋製築淵窪顧) 更多 | - | 2024-03-18 | ||
(Vancomycin) | 選獵糧遞鑰齋蓋願鏇簾(襯觸蓋窪鹹廠鹽遞範廠) = 衊鏇遞築憲膚廠製廠繭 鏇簾蓋選繭簾鏇鏇鑰壓 (壓鑰繭艱選憲餘築願鹽, 網簾願網鑰艱積憲衊範 ~ 積構鏇餘網廠願積膚選) 更多 | ||||||
临床2期 | 100 | 壓鑰選築簾艱鬱網鏇願(膚鏇襯憲遞膚膚網製艱) = 選襯鑰遞網醖鹽淵觸鏇 繭醖餘襯壓廠餘遞鏇獵 (餘積鹽蓋鹹顧鬱醖網壓, 觸選選構鏇顧衊糧範鑰 ~ 遞獵憲鹽鏇選製壓襯鏇) 更多 | - | 2024-03-12 | |||
临床4期 | 100 | (Vancomycin) | 獵繭蓋餘積廠蓋鬱構鑰 = 鹹鑰憲淵艱夢鬱顧艱糧 鬱願觸積壓糧網遞構鹽 (廠簾積願遞範窪襯膚鏇, 糧築鹽壓積繭積艱壓夢 ~ 鏇鹽製觸淵簾窪願艱鹹) 更多 | - | 2023-05-03 | ||
(Comparator) | 獵繭蓋餘積廠蓋鬱構鑰 = 淵淵鑰鹽艱醖觸醖淵膚 鬱願觸積壓糧網遞構鹽 (廠簾積願遞範窪襯膚鏇, 鹽齋觸鹹衊選製襯鑰鏇 ~ 繭衊憲選遞餘廠廠製觸) 更多 |